Drug Profile
Asunercept companion diagnostic - Apogenix/R Biopharm
Alternative Names: APG101 companion diagnostic; Apocept™ companion diagnostic; Asinercept companion diagnostic; CD95-Fc fusion protein companion diagnosticLatest Information Update: 28 Jun 2019
Price :
$50
*
At a glance
- Originator Apogenix; R-Biopharm
- Developer Apogenix
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Glioblastoma
- No development reported Myelodysplastic syndromes; Solid tumours
Most Recent Events
- 28 Jun 2019 No recent reports of development identified for clinical-Phase-Unknown development in Myelodysplastic-syndromes(Diagnosis) in Germany
- 28 Jun 2019 No recent reports of development identified for clinical-Phase-Unknown development in Solid-tumours(Diagnosis) in Germany
- 09 Jun 2017 Phase-II development for Glioblastoma (Diagnosis) is ongoing in Germany (Apogenix pipeline, June 2017)